Less Than Half of New Drug Approvals Add Therapeutic Value Over Existing Treatments: Study

A study published in The BMJ on Wednesday reveals that the majority of new drug approvals in the U.S. and Europe do not provide significant therapeutic benefits compared to existing treatments. The study focused on 124 initial indications approved by the FDA and European Medicines Agency (EMA) between 2011 and 2020. It found that less than half of these indications, specifically 47% in Europe an..